Back to Agenda
Session 4: International Regulator Updates
Session Chair(s)
Emer Cooke, MBA
Executive Director, European Medicines Agency, Netherlands
Biosimilar medicines are developed with worldwide ambitions for marketing authorisation holders. Most countries have now implemented a biosimilar medicines framework. This session will provide an update from 4 different regulatory bodies on where the regulatory/legal frameworks stand in their respective jurisdictions and offer insights as to the current and upcoming regulatory developments industry need to be ready for. The specific guidelines framework evolution impacting the development and registration of future biosimilar medicines will be covered as well as information on the evolution of biosimilar policy and international regulatory convergence & cooperation initiatives.
Speaker(s)
Leah Christl, PhD
Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy, Amgen, United States
Emer Cooke, MBA
Executive Director, European Medicines Agency, Netherlands
Rana Malkawi
Drug Directorate Director, Jordan Food and Drug Administration (JFDA), Jordan
Michelle Werneck de Oliveira
Helth Surveillance and Regulation Specialist, Brazilian Health Surveillance Agency (ANVISA), Brazil
Have an account?